Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
The Schedule 13G filed on 27 June 2025 discloses that The Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC have acquired beneficial ownership of 12,748,968 shares of Taysha Gene Therapies, Inc. (TSHA) common stock. The position represents 5.1 % of TSHA’s outstanding shares, crossing the 5 % reporting threshold under Section 13(d) of the Securities Exchange Act.
All voting and dispositive authority over the shares is reported as shared; neither entity claims sole authority. The filing is on Schedule 13G, indicating a passive investment rather than an effort to influence control, as confirmed by the Item 10 certification.
Goldman Sachs & Co. LLC is classified as a broker-dealer, other organization, and investment adviser, while The Goldman Sachs Group, Inc. is identified as a holding company/control person. No additional group members or activist exhibits are included.
The disclosure confirms meaningful institutional ownership by a globally recognized financial institution, potentially improving share liquidity and lending credibility to TSHA. However, because it is a passive filing, it does not imply forthcoming strategic or operational changes at the issuer.